How intestinal bacteria change the activity of anticancer drugs

Share This Post

According to a study by the University College London (UCL) on how nematodes and microorganisms treat drugs and nutrients, the activity of anticancer drugs depends on the type of bacteria that live in the intestine .

This finding highlights the potential benefits of adjusting intestinal bacteria and diet to improve the prognosis of cancer treatment and understanding the value of individual differences in drug use.

This latest study, published in the journal Cell, reports a new and efficient screening method that can explain the complex relationship between host organisms, gut microbes, and drug effects.

The treatment effect of patients with colorectal cancer varies greatly. We want to know whether this will be caused by microorganisms changing the body’s process of processing drugs. We have developed a rigorous test system that can be used for pre-clinical screening of drug interactions between the host and microorganisms, or for designing medicinal bacteria, which will make the treatment method change dramatically.

The research team found that if the host-microbe-drug interaction is not taken into account, the combined treatment of cancer may be limited.

We have highlighted a critical missing piece about how drugs treat diseases. We plan to continue in-depth research in this area to confirm which microorganisms will affect human drug activity, and through the supervision of dietary supplements, may have a huge impact on the prognosis of cancer treatment.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

After amazing growth of CAR T-Cell therapy what's next
CAR T-Cell therapy

After amazing growth of CAR T-Cell therapy: what’s next?

CAR T-cell therapy has rapidly transformed cancer treatment by reprogramming a patient’s T-cells to attack cancer cells, demonstrating remarkable success in hematologic cancers. Advances in genetic engineering, regulatory support, and investment are driving further expansion. Researchers are now tackling the challenges of applying this therapy to solid tumors, aiming to enhance efficacy and accessibility, marking a new era in personalized cancer therapy and immunotherapy.

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy